Member Info for technick

LTHs will remember they changed their sales strategy from a software sales to a per analysis sale. As more installs are done these sales exponentially rise. £100m-£200m market cap within reach short term so £0.60 to £1.00 per share... imo

... the US investors will start piling in after 1:30 this afternoon and we should see this climb again. Interesting to see how many shares the MMs picked up for this afternoon on that dip

we'll see a levelling off until 1:30 then a steady climb if yesterdays pattern is repeated, that will demonstrate US investor interest is in play

They do

clear the old, make way for the new

Trek, I would argue that ONC are a different business, for me the biggest different (apart from the obvious technology base) is that IB is a US company. US investors will see this as an opportunity. At some point IB/IQAI will be either sold to a US entity, or list on NASDAQ to achieve a greater return potential. This is all gearing up nicely to achieve significant market cap in my opinion.

If there is US investor interest the SP should continue to climb, they'll know that they'll be a US acquirer at some point, very few medical AI companies out there, less with FDA approved products. FDA approval for software and in particular AI is not easy

I think you have to look at the potential exits here to work out valuation. I bought in here at the end of 2018, I sold my original investment on the first spike (not the top) and kept the profit locked in. My belief is that as a US-based enterprise, now with a suite of software and FDA approvals, some sales traction taking shape, that this is a US acquisition target.

You need to view it in that way in terms of valuation. I think somewhere north of £100m or £1 a share is possible and probably sooner rather than later.

And remember with StoneChecker they were talking to several suitors.

For competitor or commercial reasons (ie not telling other customers) sales values will never be disclosed publicly, look to end of year results for those as a whole.

Similar strategy for other tech companies, build the IP and sell the asset to larger players with broader sales and marketing reach... the fact we are seeing US interest suggest this process will create visibility with potential acquirers

Claire, I agree, this is a trade sale with a lot of IP, software and forward sales

The FDA don’t award approvals without significant demonstration. The Company has been very shrewd over the last few years. Strong position, great company, FDA approvals allows significant market entry.

The pick up at 1:30-2:00pm possibly shows this is being picked up by US investors. Did someone say we were tipped by a US investor blog?

I suspect the uptick since 1pm was interest from US traders as well bearing in mind IB is located in the US. Surely a takeover target shortly and why IQAI took stonechecker back in

This could easily get to a market cap of ca. £50m which would give a SP of over £1.10p

Agree Claire, this puts IQ-AI at in the front tier now...

If this was a US NASDAQ company we'd be in excess of £100m market cap in my opinion, but snapped up by Google or some other AI play... I wonder where we will end up valuation wise?

I tend to agree with Trek, this could offer a short term flip for the BOD. There is a value inflection point here were there is a significant value versus investment required to turn it into a revenue acquisition. It's been obvious that the business has been about creating IP value, and my opinion is that this is because they wish to sell the business. I wonder if this also lead to the decision to keep hold of stronechecker. Time will tell. It's still a significant re-rate in my opinion.

Another great RNS, all adds value to the business and opens commercialisation routes

Mags, Genedrive have made statements saying their CE-IVD mark allowed them to start selling within the EU and that they intended to do so. If they had no sales they would have to make an announcement, arguably more so than if they had made sales. It's ok for me to have an opinion and it's ok for me to have an opinion thats different to yours. I respect yours and often agree. On this one thought I suspect you are not correct and some sales have been booked already. We shall see shortly...